KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin: 2010-2025

Historic Gross Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to 62.83%.

  • Emergent BioSolutions' Gross Margin rose 456.00% to 62.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 105.83%, marking a year-over-year increase of 679.00%. This contributed to the annual value of 73.55% for FY2024, which is 268.00% up from last year.
  • Emergent BioSolutions' Gross Margin amounted to 62.83% in Q3 2025, which was up 19.63% from 52.52% recorded in Q2 2025.
  • Emergent BioSolutions' Gross Margin's 5-year high stood at 247.56% during Q4 2024, with a 5-year trough of 6.94% in Q1 2023.
  • For the 3-year period, Emergent BioSolutions' Gross Margin averaged around 79.60%, with its median value being 55.40% (2024).
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 12,191bps in 2022, then crashed by 6,672bps in 2023.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Gross Margin stood at 39.90% in 2021, then surged by 12,191bps to 161.81% in 2022, then soared by 1,581bps to 177.62% in 2023, then skyrocketed by 6,994bps to 247.56% in 2024, then spiked by 456bps to 62.83% in 2025.
  • Its Gross Margin was 62.83% in Q3 2025, compared to 52.52% in Q2 2025 and 60.17% in Q1 2025.